Danaher Corporation (NYSE:DHR) Holdings Raised by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 6.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,998,289 shares of the conglomerate's stock after purchasing an additional 115,228 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.28% of Danaher worth $409,649,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Norges Bank purchased a new stake in Danaher in the 4th quarter worth about $2,130,740,000. GAMMA Investing LLC lifted its stake in Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after acquiring an additional 1,863,381 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Danaher in the 4th quarter worth about $391,172,000. Two Sigma Advisers LP increased its position in Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after purchasing an additional 1,601,800 shares during the last quarter. Finally, Capital World Investors increased its position in Danaher by 32.7% in the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after purchasing an additional 1,566,658 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on DHR. The Goldman Sachs Group dropped their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Leerink Partners upped their target price on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Guggenheim reaffirmed a "buy" rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, April 23rd. Evercore ISI dropped their target price on Danaher from $240.00 to $230.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 22nd. Finally, Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and an average price target of $248.61.

Insider Buying and Selling

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $198.20 on Friday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The firm has a market capitalization of $141.84 billion, a PE ratio of 38.48, a PEG ratio of 2.83 and a beta of 0.77. The business's 50 day moving average is $194.84 and its 200-day moving average is $208.52. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.